Quality Improvement Project to Increase Human Papillomavirus Two-Dose Vaccine Series Completion by 13 Years in Pediatric Primary Care Clinics
The human papillomavirus (HPV) causes genitourinary and oropharyngeal cancers. The HPV vaccine is safe and effective in preventing those diseases; however, vaccine series completion rates remain low in the United States. Our quality improvement (QI) project aimed to increase HPV-vaccination series completion rates to 70% from 2017 to 2020 for the 13-year patient population in an extensive academic pediatric primary care network that serves predominantly minority and Medicaid-insured children in Columbus, OH.
Source: Journal of Adolescent Health - Category: Child Development Authors: Amina Smajlovic, Christina D. Toth Tags: Original article Source Type: research
More News: Academia | Cancer | Cancer & Oncology | Cancer in Adolescents | Cancer Vaccines | Cervical Cancer Vaccine | Child Development | Children | Genital Warts | Human Papillomavirus (HPV) | Insurance | Medicaid | Oropharyngeal Cancer | Pediatrics | Primary Care | USA Health | Vaccines